Download presentation
Presentation is loading. Please wait.
Published byHoratio Bruce Modified over 6 years ago
1
Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report Benjamin Nisman, PhD, Hovav Nechushtan, MD, PhD, Haim Biran, MD, Hadas Gantz-Sorotsky, MD, Nir Peled, MD, Simon Gronowitz, PhD, Tamar Peretz, MD Journal of Thoracic Oncology Volume 9, Issue 10, Pages (October 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1 Survival for 233 patients with non–small-cell lung cancer (A) and 91 patients with small-cell lung cancer (B). Kaplan-Meier estimates according to pretreatment serum TK1 activity. TK1, thymidine kinase. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2 Kaplan-Meier estimates according to the ratio between two measurements of TK1 activity before the first and second (A) or third (B) cycles of chemotherapy in 96 patients with lung cancer. TK1, thymidine kinase. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.